NCT07444047Recruiting
MRI-Based Lesion Differentiation in Older Patients With Multiple Sclerosis
Quantitative Susceptibility Mapping for Lesion Differentiation in Aging Multiple Sclerosis
Source: ClinicalTrials.gov · Last updated 1 Jun 2026
Brief summary (registry, in English)
This study investigates whether an advanced MRI technique called Quantitative Susceptibility Mapping (QSM) can improve the differentiation of white matter lesions in people aged 50-70 years with multiple sclerosis (MS). In older individuals with MS, white matter changes seen on MRI may be related to MS or to other types of white matter changes, most commonly age-related changes or chronic small vessel disease. These conditions can appear similar on conventional MRI scans, making interpretation challenging. Participants will undergo routine clinical MRI, including a short additional QSM sequence, as well as brief cognitive and physical assessments. A comparison group with cerebral small vessel disease will also be included. The goal of the study is to determine whether QSM can provide more precise lesion characterization and support more accurate clinical interpretation of MRI findings in older patients with MS.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 1000 (estimated)
- First submitted
- 19 Feb 2026
- Start date
- 11 May 2026
- Primary completion date
- 31 Dec 2030
- Lead sponsor
- Oslo University Hospital
- Diseases
- Multiple sclerosis
- NCT number
- NCT07444047
What you commit to
- Study type: Observational
- Planned participants: 1000
- From 11 May 2026 to the primary completion date, 31 Dec 2030
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe psychiatric comorbidity
- Severe psychiatric comorbidity
Other
- MRI contraindications
- Major functional disability unrelated to MS or CSVD
- MRI contraindications
- Probable or definite cerebral amyloid angiopathy according to Boston criteria 2.0
- Genetic or inflammatory vasculopathies
- Persistent neurological deficits
- Major functional disability unrelated to CSVD
Who the study is looking for
- Age 50-70 years
- Clinically confirmed diagnosis of multiple sclerosis
- Participation in the AgeMS study at Oslo University Hospital
- Age 50-80 years
- Radiological evidence of hypertensive small vessel disease on MRI
- Good clinical recovery following transient ischemic attack (TIA), minor stroke, or stroke mimic diagnosis
Age in the registry: 50 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Oslo University Hospital Coordinator of this site? Confirm its status | Oslo | Norway | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.